August 29, 2025

Gastrointestinal Foreign Bodies: When to Use Computed Tomography Versus Radiograph

A physician-focused review of gastrointestinal foreign body ingestion is looking to guide triage and intervention.

Conexiant

August 18, 2025

'Social Apnea' Highest on Saturdays

Weekend catch-up sleep and social jetlag may increase obstructive sleep apnea severity.

Conexiant

July 18, 2025

New Guideline Sets Standards for Sinus Surgery

A new guideline outlines when surgery is appropriate for chronic rhinosinusitis, urging clinicians to confirm diagnosis, assess candidacy, and consider long-term management needs.

Conexiant

August 04, 2025

Diphenhydramine Risks Outweigh Benefits

Researchers urge physicians to reconsider diphenhydramine use due to safety concerns, high sedation risk, and safer second-generation antihistamine alternatives.

Conexiant

June 19, 2025

Chronic Cannabis Use Linked to Vascular Impairment

A new cross-sectional study in healthy adults found that chronic marijuana smoking and edible THC use were linked to reduced endothelial function, an early marker of vascular disease risk.

Conexiant

July 31, 2025

Trial Tests Fixed Nitrous Oxide for Dental Scaling

Researchers aim to improve dental patient care by testing a fixed nitrous oxide–oxygen mix to address anxiety and discomfort during routine ultrasonic scaling procedures.

Conexiant

July 23, 2025

Mouth Taping Shows Limited Benefit, Possible Risk

A review of 10 studies with 233 patients found limited benefits and potential safety risks associated with mouth taping for obstructive sleep apnea and mouth breathing during sleep.

Conexiant

June 23, 2025

Is Smoking a Surgical Risk Multiplier?

A study of nearly 700 patients found that smokers undergoing surgery for esophageal cancer experienced significantly more complications, including higher rates of pneumonia and respiratory distress, than nonsmokers—though smoking did not independently impact long-term survival.

Conexiant

June 16, 2025

Cytisinicline Shows Efficacy In Smoking Cessation Trial 

A phase 3 randomized clinical trial found that cytisinicline, a partial agonist at α4β2 nicotinic acetylcholine receptors, improved smoking cessation rates compared with placebo, with higher abstinence rates and reduced craving over 24 weeks.

Conexiant